Eligard is a brand-name injectable drug prescribed to help manage symptoms of advanced prostate cancer in adults. As with other drugs, Eligard can cause side effects, such as fatigue, hot flashes, and ...

Eligard (leuprolide) is a brand-name injection that’s prescribed for advanced prostate cancer in adults. Eligard has interactions with some other drugs. Examples include certain antidepressants and ...

Eligard, a palliative treatment for advanced prostate cancer, incorporatesa luteinizing hormone-releasing hormone agonist, or LHRH agonist, known asleuprolide acetate with QLT USA's proprietary ...

The active ingredient of Eligard® is leuprorelin acetate, a powder which is solubilized with a solvent for subcutaneous injection. Eligard® is available in three different dosages (for 1-month, ...

CHICAGO, July 24, 2019 (GLOBE NEWSWIRE) -- Tolmar Pharmaceuticals, Inc. today announced the publication of a study of nadir testosterone (T) levels achieved in pivotal trials for ELIGARD ® (leuprolide ...

Dear Dr. Roach: I am 63 and was diagnosed with aggressive prostate cancer in 2020. I had my prostate removed. Unfortunately, they found that the cancer had spread to the lymph nodes. I have since had ...

Hanall Biopharma is strengthening its position in the prostate cancer treatment market, achieving record-breaking sales as of August with Eligard. Hanall Biopharma announced on the 24th that its ...

Eligard is a luteinizing hormone-releasing hormone (LHRH) agonist. Tolmar announced that the Food and Drug Administration (FDA) has approved a label update for Eligard (leuprolide acetate for ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I am 63 and was diagnosed with aggressive prostate cancer in ...

Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Martinsried - San Diego, May 4, 2004. Eligard®, the first drug of the German-American ...

Feb 9 (Reuters) - QLT Inc. said its subsidiary will pay $112.5 million to settle a patent infringement lawsuit related to its prostrate cancer drug Eligard. As a result of the settlement with TAP ...

Dear Dr. Roach: I am 63 and was diagnosed with aggressive prostate cancer in 2020. I had my prostate removed. Unfortunately, they found that the cancer had spread to the lymph nodes. I have since had ...